Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D Supplementation and Neurocognitive Function in Older Adults
NCT03019120Phase 2
Key facts
- Status
- Withdrawn
- Start
- Jan 2017
- Primary completion
- Feb 2020
- Countries
- 1
- Sponsor
- Rambam Health Care Campus
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Drugs
- vitamin d
- Conditions
- Vitamin D deficiency (VDD)neurocognitive disorder (NCD)
01
Overview
Phase 2, open-label trial of vitamin d in Vitamin D deficiency (VDD) and neurocognitive disorder (NCD), sponsored by Rambam Health Care Campus. Primary endpoint: Neurotrax computerized cognitive assessment at 3 months. Planned start Jan 2017; status: withdrawn.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Adults aged 65 and older with vitamin D deficiency (< 30 ng/ml), stable health, and normal baseline cognitive function.
04
Endpoints
Primary
Neurotrax computerized cognitive assessment
Beyond the preview
Go deeper on NCT03019120.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019120.